Si Sun

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Correction: Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.

Correction: Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: February 12, 2026

Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy.

Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 28, 2025

Liquid-liquid phase separation of CBX2 regulates lipid raft-mediated extracellular vesicle biogenesis to facilitate ovarian carcinoma metastasis.

Liquid-liquid phase separation of CBX2 regulates lipid raft-mediated extracellular vesicle biogenesis to facilitate ovarian carcinoma metastasis.

Journal: NPJ precision oncology

Published: August 29, 2025

CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer.

CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer.

Journal: Cell death & disease

Published: August 19, 2025

Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.

Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: July 12, 2025

Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer.

Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 05, 2025

The cyclin-dependent kinase inhibitor p27 facilitates chemosensitivity by promoting ferroptosis in epithelial ovarian cancer.

The cyclin-dependent kinase inhibitor p27 facilitates chemosensitivity by promoting ferroptosis in epithelial ovarian cancer.

Journal: The Journal of biological chemistry

Published: April 22, 2025

Risk assessment in a Chinese cohort of 96 318 females undergoing opportunistic cervical cancer screening.

Risk assessment in a Chinese cohort of 96 318 females undergoing opportunistic cervical cancer screening.

Journal: The oncologist

Published: April 17, 2025

Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness.

Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: March 11, 2025

LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.

LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.

Journal: Oncogene

Published: December 30, 2024

Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation.

Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation.

Journal: Molecular pharmaceutics

Published: July 24, 2024

CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness.

CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness.

Journal: The Journal of biological chemistry

Published: July 13, 2024

Showing 1-12 of 78

Last Updated: 09/26/2026